Breaking News Instant updates and real-time market news.

GILD

Gilead

$67.46

-0.28 (-0.41%)

08:37
07/11/19
07/11
08:37
07/11/19
08:37

Gilead, Renown IHI announce collaboration to enhance understanding of NASH

Gilead and the Renown Institute for Health Innovation, or IHI, announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis, or NASH and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease, or NAFLD as well as a control cohort of 40,000 individuals in Nevada. Renown Health maintains electronic health records for 1.02M registered patients.

  • 22

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

GILD Gilead
$67.46

-0.28 (-0.41%)

07/02/19
CANT
07/02/19
NO CHANGE
Target $88
CANT
Overweight
Cantor boosts Gilead target to $88 on moved up filgotinib timeline
Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences to $88 from $87 and reiterates an Overweight rating on the shares. The "positive" U.S. filing update for filgotinib could move timelines up by at least a year, Young tells investors in a research note. The analyst's prior base case assumed a 2022 U.S. launch with sales of $93M. Following last night's update, the analyst shifted her timelines for a potential late-2020 approval.
07/02/19
STFL
07/02/19
NO CHANGE
Target $121
STFL
Buy
Gilead news for filgotinib a positive for Galapagos, says Stifel
After Gilead (GILD) announced last night that its recent pre-New Drug Application meeting with the FDA established a path for an NDA submission for filgotinib in rheumatoid arthritis in 2019, Stifel analyst Adam Walsh called the news a positive for partner Galapagos (GLPG). Galapagos investors have been concerned that the phase 2 MANTA study of testicular toxicitiy would be a gating factor for the NDA submission but last night's news largely removes that uncertainty, said Walsh, who keeps a Buy rating and $121 price target on Galapagos shares.
07/03/19
RBCM
07/03/19
NO CHANGE
Target $91
RBCM
Outperform
RBC sees 'compelling buying opportunity' with Gilead through overhangs
With many key overhangs that had kept investors on the sidelines now lifted, shares of Gilead Sciences offer a "compelling buying opportunity," RBC Capital analyst Brian Abrahams tells investors in a research note. This week's regulatory clarity on Filgotinib is a "big win," and the impact of ViiV's dual regimen Dovato on Gilead's HIV franchise is not as competitive as once seemed, contends the analyst. He believes Gilead's valuation "looks cheap and at a floor." Shares at current levels do not fully reflect the company's base business, let alone its pipeline potential, says Abrahams, who sees "many reasons" for investors to take another look at the stock. The analyst reiterates an Outperform rating on Gilead with a $91 price target. The stock in morning trading is down 39c to $68.45.
07/10/19
FBCO
07/10/19
NO CHANGE
Target $70
FBCO
Neutral
Gilead should maintain market share in HIV, says Credit Suisse
Credit Suisse analyst Evan Seigerman says that his physician survey suggests Gilead is well positioned to maintain market share in HIV despite increasing competition. The survey of 30 U.S.-based physicians demonstrated high physician preference for Gilead regimens, with low switch rates and high stability on therapy, he adds, noting that competition from generics and dual therapies was viewed as modest. Based on the survey, Seigerman believes that Gilead will remain the dominant player in HIV, led by continued success of Biktarvy and other TAF-based regimen. While the analyst is positive on the HIV franchise, and believes that sales from these products will support the revenue base-near term, much of the growth is well appreciated by consensus estimates and fairly reflected in the stock-supportive of his Neutral rating and $70 price target for the shares.

TODAY'S FREE FLY STORIES

ERYP

Erytech Pharma

$6.69

(0.00%)

16:24
07/16/19
07/16
16:24
07/16/19
16:24
Syndicate
Erytech Pharma files to sell $100M of ADSs »

Representing ordinary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.57

1.05 (1.34%)

16:23
07/16/19
07/16
16:23
07/16/19
16:23
Earnings
CSX sees FY19 revenue down 1%-2% vs. prior view of growth »

CSX sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

INAP

Internap

$3.56

0.13 (3.79%)

16:22
07/16/19
07/16
16:22
07/16/19
16:22
Hot Stocks
Internap to streamline organization, initiates search for new CFO »

Internap announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNF

Fidelity National

$41.57

0.02 (0.05%)

16:21
07/16/19
07/16
16:21
07/16/19
16:21
Earnings
Fidelity National reports Q2 adjusted EPS 92c, consensus 87c »

Reports Q2 revenue $2.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 01

    Aug

  • 13

    Nov

RM

Regional Management

$26.62

-0.28 (-1.04%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Hot Stocks
Regional Management appoints Robert Beck CFO »

Regional Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 16th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$15.54

-0.65 (-4.01%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Whiting Petroleum names Correne S. Loeffler CFO »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 27

    Aug

UAL

United Continental

$94.00

2.7 (2.96%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX Q2 CapEx down to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

BPMX

BioPharmX

$0.44

-0.0183 (-3.97%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
BioPharmX appoints Steven Bosacki COO »

BioPharmX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCCL

China Ceramics

$0.87

(0.00%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
China Ceramics receives Nasdaq notification of non-compliance »

China Ceramics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
United Continental reports Q2 total passenger revenue up 6.1% y/y »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KSFTF

Kingsoft

$0.00

(0.00%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Downgrade
Kingsoft rating change  »

Kingsoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.68

1.16 (1.48%)

16:13
07/16/19
07/16
16:13
07/16/19
16:13
Hot Stocks
CSX reports Q2 operating ratio fell to 57.4% since Q2 last year »

Last year's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PDD

Pinduoduo

$20.13

0.77 (3.98%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Pinduoduo rating change  »

Pinduoduo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.